Skip to Content

'
Faye M. Johnson, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: Unit 432
Houston, TX 77030
Room Number: FC9.3036
Phone: 713-792-6363
Fax: 713-792-1220

Education & Training

Degree-Granting Education

1996 University of Texas Medical School at Houston, Houston, TX, MD, Medicine
1996 University of Texas Graduate School of Biomedical Sciences M.D. Anderson Cancer Center, Houston, TX, PHD, Cancer Biology
1989 The Johns Hopkins University, Baltimore, MD, BA, Biology

Postgraduate Training

6/2002-6/2003 Chief Medical Oncology Fellow, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
2000-2002 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
1997-2000 Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX

Board Certifications

2003 Medical Oncology
2000 Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2003-8/2010

Institutional Committee Activities

Member, Faculty Senate, MD Anderson Cancer Center, 9/2010-present
Member, Faculty Appeals Committee, MD Anderson Cancer Center, 7/2009-present
Member, Medical Practice Committee, MD Anderson Cancer Center, 2/2006-present

Honors and Awards

2011 Nominee in Recognition of Mentoring Excellence, MD Anderson Post-Doctoral Association
2010 Nominee in Recognition of Mentoring Excellence, MD Anderson Post-Doctoral Association

Selected Publications

Peer-Reviewed Original Research Articles
1. Sen B, Peng S, Saigal B, Williams M and Johnson FM. Distinct interactions between c-Src and C-Met in mediating resistance to c-Src inhibition in head and neck Cancer. Clinical Cancer Research. In Press.
2. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran H, Erasmus JJ, Hwang L, Takebe N, Blumenschein G, Lippman SM, and Stewart DJ. Phase II Study of Dasatinib in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Clinical Oncology 28(30):4609-4615, 10/2010.
3. Rothschild S, Gautschi O, Haura E, Johnson F. Src inhibitors in Lung Cancer: Current Status and Future Directions. Clinical Lung Cancer 11(4):238-42, 7/2010. PMID: 20630825.
4. Haura EB, Camidge R, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K and Carbone D. Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy. Journal of Thoracic Oncology 5(6):S207, 6/2010.
5. Lai S and Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches. Drug Resistance Updates 13(3):67-78, 5/2010.
6. Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 29(18). e-Pub 2/2010. PMCID: PMC20154724.
7. Johnson FM, Arawal S, Burris H, Rosen L,Dhillon, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA. Phase I, Pharmacokinetic, and Drug Interaction Study of Dasatinib in Patients with Advanced Solid Tumors. Cancer 15(116(6)):1582-91, 1/2010. PMID: 20108303.
8. Johnson FM and Glisson BS. Irinotecan or etoposide as front-line therapy for SCLC? Nature Reviews Cancer 6:562-563, 11/2009.
9. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach J, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clinical Cancer Research 15(22):6852-61, 11/2009.
10. Brannan JB, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM. Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer. Clinical Cancer Research 15(13):4423-4430, 7/2009. PMID: 19531623.
11. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II Study of the Efficacy of the Anti-Insulin-like Growth Factor Type 1 Receptor Antibody Cp-751,871 in Combintation wiht Paclitazel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer. J Clin Oncol 27(15):2516-22, 5/20/2009. e-Pub 4/20/2009. PMID: 19380445.
12. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src Inhibition Results in STAT3 Activation and Cancer Cell Survival via Altered JAK-STAT3 Binding. Cancer Research 69(5):1958-65, 3/2009.
13. Brannan JM, Sen B, Saigal B, Prudin L, Behrens C, Dong W, Bekele BN, Wistuba I and Faye Johnson. EphA2 in the Early Pathogenesis and Progression on Non-smallCell Lung Cancer. Cancer Prevention Research 2(12):1039-49, 2009.
14. Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 26(20):3460-2, 7/2008. PMID: 18612164.
15. Saigal B, Glisson BS, Johnson FM. Dose-and Sequence-dependent Cyotoxicity of Erlotinib and Docetaxel in Head and Neck Squamous Cell Carcinoma. Anticancer Drugs 19(5):465-475, 6/2008. PMID: 18418213.
16. Mandal M, Myers JN, Lipman SM, Johnson FM, Williams MD, Rayala S, Ohshiro K, Rosenthal DI, Weber RS, Gallick GE,El-Naggar AK. Epithelial to mesenchymal transition in head and neck squamous carcinoma: associationof Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 112(9):2088-100, 5/2008. PMID: 18327819.
17. Yang Y, Wislez M, Fujimoto N, Prudkin L, Izzo JG, Uno F, Ji L, Hanna AE, Langley RR, Liu D, Johnson FM, Wistuba I, Kurie JM. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 7(4):952-60, 4/2008. PMID: 18413809.
18. Johnson FM and Gallick GE. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7(6):651-9, 11/2007. PMID: 18045060.
19. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-72, 7/2007. PMID: 17620427.
20. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366-76, 1/2007. PMCID: PMC1762707.
21. Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src Kinase Inhibition results in Synergistic Antitumor Effects. Clin Cancer Res 13(14):4233-4244, 2007. PMID: 17634553.
22. Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in small cell lung cancer cells. Cancer 106(2):366-74, 1/2006. PMID: 16342249.
23. Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 63(3):717-24, 11/2005. PMID: 16199307.
24. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11(19):6924-32, 11/2005. PMID: 16203784.
25. Johnson FM, Saigal B, Donato NJ. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cell. J Cell Physiol 205(2):218-27, 11/2005. PMID: 15887238.
26. Johnson FM, Yang P, Newman RA, Donato NJ. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate. J Exp Ther Oncol 4(4):317-25, 12/2004. PMID: 15844661.
27. Johnson FM, Garden A, Palmer JL, Kies M, Clayman G, Brumfield B, Khuri FR, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A Phase II study of Docetaxel and Carboplatin as Neoadjuvant Therapy for patients with advanced Nasopharyngeal Carcinoma. Cancer 100(5):991-8, 3/2004. PMID: 14983495.
28. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park) 17(7 Suppl 7):17-21, 7/2003. PMID: 12886869.
29. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I Study of Dose-Dense Alternating Therapy with Irinotecan/Cisplatin and Etoposide/Cisplatin for Patients with Small-Cell Lung Cancer. Clin Lung Cancer 5(1):40-5, 7/2003. PMID: 14596703.
30. Kim ES, Johnson F, Hong WK, Khuri FR. Strategies in the Chemoprevention of Lung Cancer. Chemoprevention, 2003.
31. Johnson FM, Shur BD. The level of cell surface beta1,4-galactosyltransferase I influences the invasive potential of murine melanoma cells. J Cell Sci 12(16):2785-95, 7/1999. PMID: 10413685.
32. Johnson FM, Garcia A. Sepsis with group B streptococci (Streptococcus agalactiae) secondary to urinary tract infection in an adult male. J Am Geriatr Soc 47(5):629-30, 5/1999. PMID: 10323662.

Abstracts
1. Sen B, Peng S, Johnson FM. JAK/STAT activation following Src inhibition is mediated by the loss of SOCS2 expression. American Association for Cancer Research (#4005), 2010.
2. Johnson FM, Bekele Nebiyou B, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus J, Hwang L, Takebe N, Blumenschein G, Lippman S, Stewart D. Phase II Study of Dasatinib in Patients with Advanced Non–Small Cell Lung Cancer. American Society of Clinical Oncology (#7594), 2010.
3. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in JAK activation and cancer cell survival via altered SOCS expression. American Association for Cancer Research, Denver CO (#4375), 3/2009. PMID: 19223541.
4. Byers AL, Sen B, Saigal B, Nanjundam, Mills G, Heymach J, Johnson FM. Reciprocal regulation of Src and STAT3 activation in non-small cell lung cancer. American Association for Cancer Research Annual Meeting, Denver CO (#1531), 2009.
5. Brannan JM, Ozburn NC, Prudkin ML, Dong W, Bekele BN, Wistuba II, Johnson FM. Knockdown of the tyrosine kinase EphA2 leads to decreased migration and colony size in non-small cell lung cancer (NSCLC) cell lines. American Association for Cancer Research Annual Meeting (#3535), 2008.
6. Raju U, Johnson FM, Glisson BS, Riesterer O, Milas L, Ang KK. Mechanisms of enhanced radiosensitivity of human head and neck squamous cell carcinomas by dasatinib (BMS-354825, an inhibitor of Src kinases) include induction of apoptosis and inhibitionof DNA repair. American Association for Cancer Research Annual Meeting, San Diego, CA (#642), 2008.
7. Saigal B,Johnson FM. Pathways mediating apoptosis and cell cycle arrest downstream of Src family kinases in aerodigestive tumors. American Association for Cancer Research Annual Meeting (#4864), 2008.
8. Sen B, Saigal B, Johnson F. STAT3 knock down following Src kinase inhibition enhances aotosis. American Association for Cancer Research Annual Meeting, San Diego, CA (#5274), 2008.
9. Saigal B, Donato N, Tran HT, Johnson FM. Abrogation of STAT3 reactiation aftr Src kinase inhibition results in synergistic anti-tumor effects. American Association for Cancer Research Annual Meeting, Los Angles, CA (#2382), 2007.
10. Xu L, Nilsson MB, Hanrahan E, Cascone T, Yang Y, Du D, Prudkin L, Liu D, Engelman, J, Johnson F, Kurie J, Wistuba I, Heymach JV. Activated EGFR regulates invasiveness of Non-Cell Lung Cancer through HIF-1α mediated MET expression and is associated with increased Met levels in tumors from NSCLC patients. American Association for Cancer Research Annual Meeting, Los Angles, CA (#345), 2007.
11. Tsao A, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba II, Johnson FM. Activated Src kinase is expressed in malignant pleural mesothelioma tumors; dasatinib inhibition leads to cytotoxicity, cell cycle inhibition, and prevention of invasion and migration. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois (#7713), 2007.
12. Raju U, Koto M, Johnson FM, Glisson B, Milas L, Ang K. Molecular determinants of head and neck squamous cell carcinoma radioresistance. Molecular determinants of head and neck squamous cell carcinoma radioresistance: A novel treatment strategy to improve radiotherapy outcome. American Association for Cancer Research Annual Meeting, Los Angles, CA (#3108), 2007.
13. Luo F , Wu C, McCann B, Mayfield S, Johnson F, Burris S, Chiappori A, Rosen L, Galbraith S, Blackwood-Chirchir A. Phase I Study (CA180021-Segment 1) to evaluate the effect of ketoconazole on the pharmacokinetics of dasatinib in patients with advanced solid tumors. American Association for Cancer Research Annual Meeting, Los Angeles, CA (#932), 2007.
14. Glisson B, Saigal B, Xu Y, Johnson F. Sequence-dependent cytoxicity of docetaxel and erlotinib in head and neck squamous cell carcinoma (HNSCC). American Society of Clinical Oncology Annual Meeting, Chicago, Illinois (#6084), 2007.
15. Kopetz S, Wu J, Donato N, Davies M, Parikh N, Gallick G, Johnson F. Synergistic activity of Src and EGFR inhibitors in colon cancer. American Association for Cancer Research Annual Meeting, Los Angeles, CA (#4079), 2007.
16. Brannan JM, Ozburn NC, Prudkin ML, Massarelli E, Bekele BN, Lopez-Berestein G, Sood AK, Wistuba II., Johnson FM. The presence of Ras mutations in NSCLC tissues correlates with increased expression of the receptor tyrosine kinase EphA2. American Association for Cancer Research Annual Meeting, Los Angles, CA (#2364), 2007.
17. Bakkannagari S, Saigal B, He D, Wistuba I, Hong WK, Johnson FM, Tsao AS. Inhibition of Src kinase in mesothelioma cell lines leads to cytotoxicity, inhibition of migration, and decreased invasion. American Association for Cancer Research Annual Meeting, Washington, D.C (#3795), 2006.
18. Zhang J, Kalyankrishna S, Johnson F, Kurie JK. Src is constitutively activated in non-small cell lung cancer cells with mutant epidermal growth factor receptor and contributes to cell surviva. American Association for Cancer Research Annual Meeting, Washington, DC (#171), 2006.
19. Johnson FM, Saigal B, Talpaz M, Donato NJ. BMS-354825 multiple oncogenic tyrosine kinase inhibitor induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) cells. American Association for Cancer Research Annual Meeting, Anaheim, CA (#674), 2005.
20. Johnson FM, Tran HT, Johanson MJ, Prieto VG, Tamboli P, Peeples B, Glisson BS. Phase I trial of imatinib mesylate, cisplatin, and irinotecan in small cell lung cancer. International Chicago Symposium on Malignancies of the Chest and Head and Neck, Chicago, IL, 2004.
21. Johnson FM, Garden A, Kies M, Clayman G, Brumfield B, Khuri F, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A phase II study of docetaxel and carboplatin as neoadjuvant therapy for patients with low T, High N stage nasophryngeal carcinoma. American Society of Clinical Oncology Annual Meeting, Chicago, IL (#2053), 2003.
22. Johnson FM, Yang P, Newman RA, Talpaz M, Donato NJ. The tyrosine kinase inhibitor ST1571 induces COX-2 expression and PGE2 accumulation in head and neck squamous cell carcinoma (HNSCC) via activation of MAPK. American Association for Cancer Research Annual Meeting, Washington, D.C. (#4862), 2003.
23. Johnson FM, Donato NJ, Talpaz M. Gleevec induces cell cycle arrest, apoptosis, and activation of MAPK in head and neck squamous carcinoma cells. American Association for Cancer Research Annual Meeting, San Francisco, California (#4192), 2002.
24. Johnson FM, Kurie JM, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I trial of weekly etoposide, cisplatin, and irinotecan with G-CSF in patients with small cell lung cancer. American Society of Clinical Oncology Annual Meeting,Orlando, Flordia (#1244), 2002.
25. Johnson FM and Shur BD. Cell Surface ß1,4-galactosyltransferase facilitates invasion and metastasis of K1735 murine melanoma cells. American Association for Cancer Research, Cancer: the interface between basic and applied research, Baltimore, MD (#438), 1995.

Book Chapters
1. Gibbons D, Pisters KM, and Johnson FM. Non-small Cell Lung Cancer. In: MD Anderson Manual of Clinical Oncology. In Press.
2. Johnson FM and Gallick GE. Src Family Kinase Inhibitors in Cancer Therapy. In: In Serpins and Protein Kinase Inhibitors,. Ed(s) Georgiev B, Markovski S. Nova Science Publishers, Inc., 2009.
3. Johnson FM and Pisters KM. Non-small Cell Lung Cancer. In: MD Anderson Manual of Clinical Oncology. Ed(s) Kantarjian HN, Koller CM, Wolff R. McGraw Hill: New York, NY, 2006.
4. Kim ES, Johnson FM, Hong WK, Khuri FR. Strategies in the Chemoprevention of Lung Cancer. In: Cancer Chemoprevention. Ed(s) Koller G, Hawk ET, Sigman CC. Human Press: Totowa, NJ, 2004.

Grant & Contract Support

Title: Targeting c-src in Head and Neck Cancer
Funding Source: National Institutes of Health
Role: Principal Investigator
Duration: 1/1/2010 - 12/31/2014
 
Title: The Receptor Tyrosine Kinase EphA2: A Potential Therapeutic Target for EGFR-Dependent Lung Cancers
Funding Source: Joan Scarangello Foundation
Role: Principal Investigator
Duration: 1/1/2009 - 12/31/2010
 
Title: SPORE in Lung Cancer
Funding Source: NIH
Role: Co-Investigator
Principal Investigator: Minna J, Roth J
Duration: 5/1/2008 - 4/30/2013
 
Title: Phase II Study of Dasatinib in Non-small Cell Lung Cancer
Funding Source: Commonwealth Foundation for Cancer Research
Role: Investigator
Duration: 7/1/2007 - 12/31/2009
 
Title: Developmental Research Project
Funding Source: The University of Texas SPORE in Head and Neck Cancer
Role: Investigator
Duration: 3/1/2007 - 4/30/2008
 
Title: Career Development Award
Funding Source: The University of Texas SPORE in Lung Cancer
Role: Investigator
Duration: 9/1/2006 - 4/30/2007
 
Title: Early Therapeutics Development with Phase II Emphasis
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 1/1/2006 - 12/31/2010
 
Title: Physician Scientist Award Grant
Funding Source: MD Anderson Cancer Center
Role: Investigator
Duration: 9/1/2003 - 9/1/2008

Last updated: 11/17/2010